Payment overview · 2025
General Payments
$263.41
14 reported records · 11 companies
Healthcare provider profile · identity verified
Jason Ayres, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTHSIDE, AL · NPI 1972566776
Verified facts
What the public records show
CMS Open Payments records show Jason Ayres, MD received $263.41 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.72 | 18.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.00 | 18.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.05 | 8.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.90 | 8.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.75 | 8.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.53 | 8.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.30 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.93 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.72 | 5.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.00 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.41 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
175 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
45 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
257 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 660 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 151 |
| Omeprazole | Omeprazole | 446 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 114 |
| Simvastatin | Simvastatin | 403 | 95 |
| Losartan Potassium | Losartan Potassium | 397 | 115 |
| Clonazepam | Clonazepam | 376 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 103 |
| Meloxicam | Meloxicam | 330 | 96 |
| Lisinopril | Lisinopril | 298 | 84 |
| Metformin Hcl | Metformin Hcl | 297 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 57 |
| Carvedilol | Carvedilol | 271 | 68 |
| Ozempic | Semaglutide | 257 | 38 |
| Sertraline Hcl | Sertraline Hcl | 249 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 65 |
| Trazodone Hcl | Trazodone Hcl | 236 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 231 | 36 |
| Dexamethasone | Dexamethasone | 221 | 177 |
| Celecoxib | Celecoxib | 218 | 49 |
| Pregabalin | Pregabalin | 213 | 44 |
| Tramadol Hcl | Tramadol Hcl | 212 | 61 |
| Alprazolam | Alprazolam | 207 | 42 |
| Furosemide | Furosemide | 199 | 49 |
| Eliquis | Apixaban | 196 | 41 |
| Temazepam | Temazepam | 189 | 26 |
| Montelukast Sodium | Montelukast Sodium | 183 | 52 |
| Farxiga | Dapagliflozin Propanediol | 175 | 24 |
| Glimepiride | Glimepiride | 175 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 38 |
| Lorazepam | Lorazepam | 164 | 39 |
| Allopurinol | Allopurinol | 160 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 41 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 146 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 36 |
| Potassium Chloride | Potassium Chloride | 144 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 130 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 125 | 29 |
| Famotidine | Famotidine | 124 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 40 |
| Estradiol | Estradiol | 122 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 122 | 23 |
| Cefdinir | Cefdinir | 119 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 91 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 107 | 19 |
| Fluconazole | Fluconazole | 106 | 54 |
| Donepezil Hcl | Donepezil Hcl | 103 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 21 |
| Spironolactone | Spironolactone | 99 | 24 |
| Atenolol | Atenolol | 98 | 29 |
| Ondansetron Odt | Ondansetron | 96 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 95 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | suppressed |
| Jardiance | Empagliflozin | 91 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 90 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 22 |
| Bupropion Xl | Bupropion Hcl | 84 | 20 |
| Buspirone Hcl | Buspirone Hcl | 83 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 83 | 64 |
| Prednisone | Prednisone | 80 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 17 |
| Mirtazapine | Mirtazapine | 73 | 18 |
| Memantine Hcl | Memantine Hcl | 72 | 16 |
| Mounjaro | Tirzepatide | 72 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 56 |
| Ibandronate Sodium | Ibandronate Sodium | 71 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Xarelto | Rivaroxaban | 66 | 14 |
| Doxepin Hcl | Doxepin Hcl | 61 | suppressed |
| Fenofibrate | Fenofibrate | 60 | 14 |
| Primidone | Primidone | 60 | 13 |
| Methocarbamol | Methocarbamol | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 13 |
| Lansoprazole | Lansoprazole | 55 | 16 |
| Meclizine Hcl | Meclizine Hcl | 50 | 21 |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 46 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Colesevelam Hcl | Colesevelam Hcl | 43 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 25 |
| Diazepam | Diazepam | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 13 |
| Fentanyl | Fentanyl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Myrbetriq | Mirabegron | 40 | 12 |
| Nystatin | Nystatin | 40 | 14 |
| Valacyclovir | Valacyclovir Hcl | 40 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 21 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 39 | 38 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Flecainide Acetate | Flecainide Acetate | 38 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 38 | 22 |
| Levetiracetam | Levetiracetam | 37 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | 11 |
| Levofloxacin | Levofloxacin | 35 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 28 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Testosterone | Testosterone | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.41 · 14 records | GlaxoSmithKline, LLC. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, Korlym, NURTEC ODT, TRELEGY ELLIPTA, VENASEAL, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error